Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501177 | 0.81 | ADRA1A (0.45) | ALDH1A1KDM4EMPOCNR2LMNA | |
| SCHEMBL1051347 | 0.80 | DYRK1A (0.39) | ALDH1A1CNR2PTGER4HSD17B10MAPK8 | |
| SCHEMBL7073025 | 0.78 | GPR3 (0.43) | ALDH1A1KDM4EGAACNR1CNR2 | |
| SCHEMBL23174744 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4ECNR1CNR2HTR3E | |
| SCHEMBL29796752 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4ECNR1CNR2HTR3E | |
| SCHEMBL1894540 | 0.76 | FEN1 (0.44) | ALDH1A1KDM4EMPOCNR1CNR2 | |
| SCHEMBL23174835 | 0.75 | KDM4E (0.42) | ALDH1A1KDM4ECNR1CNR2HTR3E | |
| SCHEMBL5009531 | 0.74 | L3MBTL1 (0.45) | ALDH1A1KDM4ECNR1CNR2SMN1; SMN2 | |
| SCHEMBL17910321 | 0.74 | KDM4E (0.41) | KDM4ECNR1CNR2 | |
| SCHEMBL29585194 | 0.74 | KDM4E (0.41) | KDM4ECNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071651-B2 | 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-8071651-B2 | 5-amino-4-hydroxy-7-(imidazo [1,2-A] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-7851634-B2 | 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-7851634-B2 | 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | SPEEDEL EXPERIMENTA AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| WO-2007031558-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| EP-1764099-A2 | Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764098-A1 | Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005090305-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | CTSD, FURIN, CTSL | ALDH1A1 3038/4885KDM4E 3436/4885MPO 614/4885 |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | ALDH1A1 1013/4885KDM4E 2283/4885MPO 836/4885 |
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | CTSD, CTSL, CTSC | ALDH1A1 2618/4885KDM4E 2859/4885MPO 740/4885 |
| US-20100063087-A1 | 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | ALDH1A1 1815/4885KDM4E 2193/4885MPO 2547/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | ALDH1A1 77/4885KDM4E 2793/4885MPO 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.